LDG Laboratories Dr. Gansauge Berg, Germany – Germany
About Prof. Dr. med. Frank Gansauge
Prof. Dr. med. Frank Gansauge is a world-renowned German surgeon, oncologist, and a pioneering expert in Dendritic Cell Therapy for cancer. With over 30 years of experience, he is the Director of the LDG Laboratories, a specialised facility he founded to advance and provide innovative immunotherapies. Originally trained as a surgeon, his passion for immunology led him to become one of the most experienced specialists in dendritic cell vaccination globally. His proprietary LANEX-DC® therapy offers a new line of hope for patients with advanced cancers who have exhausted standard treatment options. Prof. Gansauge’s work is internationally recognised, holding multiple professorships and prestigious awards for his significant contributions to cancer treatment.
Medical Degrees:
- Graduation
- Medical Degree (MD, PhD), University of Tuebingen, Germany
- Habilitation (Post-doctoral degree), University of Ulm, Germany
- Medical training in Cardiff, UK
- Master’s Degree in Oncologic Surgery with Chemotherapy (2000)
- Board Certified Surgeon
- Specialist in Cancer Immunotherapy
Major Cancer Types Treated:Prof. Gansauge\'s dendritic cell therapy can be applied to a wide range of solid tumours, particularly in advanced stages, including:
- Pancreatic Cancer
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Colon Cancer
- Melanoma
- Dendritic Cell Therapy
- Cancer Immunology
- Oncologic Surgery
- Minimally Invasive Surgery
- Endocrine Surgery
- LANEX-DC® Dendritic Cell Immunotherapy: A personalised cancer vaccine created from the patient\'s own immune cells to train the body to attack tumour cells.
- Production of dendritic cell vaccines in a certified EU-GMP laboratory.
- Complex oncologic and minimally invasive surgical procedures.
Current & Past Hospital Affiliations:
- Director, LDG Laboratories Dr. Gansauge Berg (Present)
- Head, Department of Oncology and Dendritic Cell Therapy, LDG Laboratories
- Director, GPS Center for Oncological, Endocrine and Minimally Invasive Surgery, Neu-Ulm
- Head of Day Hospital and Research Laboratories, University Hospital Ulm
- Physician Assistant, Department of Surgery, University Hospital Ulm
- Visiting Professor, Liaoning University of Technology, China
- Visiting Professor, Faculty of Medicine, University of Belgrade, Serbia
- Professor, Shanxi Medical University, China
- Reviewer for renowned scientific journals.
- Co-editor of the journal Langenbeck\'s Archives of Surgery.
- Founder of LDG Laboratories, one of the leading centres for dendritic cell therapy in the world, with its own certified EU-GMP production facility.
- A global authority in the field of dendritic cell vaccination, with over 22 years of dedicated clinical practice and research in this specific area.
- Author of more than 160 scientific publications, significantly contributing to the fields of surgery, oncology, and immunology.
National & International Awards:
- Merkle Research Award (1999)
- Fred Stephans Award (1995)
- German CEO Excellence Awards (2022)
Prof. Gansauge has an extensive publication record, with a focus on pancreatic cancer, inflammation, and surgical oncology.Published Papers in Medical Journals:
- Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications in Gut (2000)
- The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis in Gut (1997)
- Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients in Archives of Surgery (1999)
- Treatment of Pancreatic Cancer: Challenge of the Facts in World Journal of Surgery (2003)
- Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells in Cancer Research (1999)
Notable Cases Handled:
- Successfully extended the lives of numerous patients with stage IV cancers who were considered \"out of options\" by conventional medicine, using LANEX-DC® therapy.
- Treated patients with advanced pancreatic cancer, one of the most challenging malignancies, with dendritic cell vaccines, often improving quality of life and survival.
- Combined his surgical expertise with immunotherapy to provide a comprehensive, multi-modal treatment plan for complex cancer cases.
Patient-Centred Care:Prof. Gansauge is dedicated to offering innovative solutions for patients, especially those in advanced stages of cancer. His approach is highly personalised, as the LANEX-DC® vaccine is created individually for each patient from their own cells. He believes in providing cutting-edge, science-driven hope, focusing on prolonging life and maintaining its quality.Technology & Innovation:Prof. Gansauge is a true pioneer at the intersection of surgery and immunology. He founded his own EU-GMP certified laboratory to have complete control over the quality and production of the dendritic cell vaccines. This commitment to innovation ensures that his LANEX-DC® therapy remains one of the most advanced and reliable forms of cellular immunotherapy available worldwide.
The cost of dendritic cell therapy is highly specific to each patient\'s case. The Cancer Rounds team can facilitate a consultation and provide a detailed treatment plan and cost estimate from Prof. Gansauge\'s clinic.
Note: The costs are indicative. A full course of therapy may involve multiple cycles. The final cost will be determined after a medical evaluation.For consultation fees, you can connect with the Cancer Rounds team.
| Treatment/Procedure | Estimated Cost (INR) | Estimated Cost (USD) |
| LANEX-DC® Dendritic Cell Therapy (per cycle) | ₹20,00,000 - ₹30,00,000 | $24,000 - $36,000 |
The Cancer Rounds team provides comprehensive support for international patients seeking treatment from Prof. Frank Gansauge.Language Support:
Prof. Gansauge\'s clinic is experienced in treating international patients, and language support can be arranged to ensure clear communication.Visa & Travel Assistance:
We assist with all aspects of your medical journey, including visa invitation letters, travel coordination, and accommodation arrangements.Pre-treatment Virtual Consultations:
We facilitate remote case reviews and virtual consultations, allowing you to discuss your eligibility for dendritic cell therapy with Prof. Gansauge\'s team before travelling to Germany.
Frequently Asked Questions
Dendritic Cell Therapy is a type of cancer immunotherapy that uses a patient's own immune cells (dendritic cells) to fight cancer. These cells are extracted from the patient's blood, activated in a lab with tumour-specific antigens, and then re-injected as a vaccine. This "trains" the patient's immune system to recognise and destroy cancer cells throughout the body.
LANEX-DC® therapy is primarily designed for patients with solid tumours in advanced stages (Stage III or IV), especially those who have already undergone standard treatments like chemotherapy or radiation without success, or who have experienced a recurrence. It is a last-line treatment that can significantly prolong life.
Yes, Prof. Gansauge is considered one of the most experienced specialists in dendritic cell therapy worldwide. He has been focused on this specific treatment for over 22 years and founded his own laboratory to perfect the process.
LANEX-DC® is a personalised cancer vaccine created in a highly controlled, EU-GMP certified laboratory under the direct supervision of Prof. Gansauge. This ensures the highest quality and potency of the vaccine, which is tailored specifically to each patient's immune system and tumour characteristics.
The first step is a medical evaluation. You can contact the Cancer Rounds team to arrange a review of your medical records by Prof. Gansauge's clinic. They will assess your case and determine if you are a suitable candidate for dendritic cell therapy.
University Hospital Heidelberg - Germany